<DOC>
	<DOCNO>NCT01755689</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity GSK Biologicals ' meningococcal vaccine GSK134612 ( MenACWY-TT ) co-administered Cervarix compare MenACWY-TT Cervarix administer alone co-administration MenACWY-TT Cervarix Boostrix compare MenACWY-TT administer alone Cervarix co-administered Boostrix .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Meningococcal Vaccine With Without Co-administration Cervarix Boostrix Female Adolescents Young Adults</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects subject ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply , requirement protocol . A female , include , 9 25 year age time first vaccination . Written inform consent obtain parents/guardian subject write informed assent obtain subject subject less legal age , write informed consent obtain subject subject achieve legal age . The legal age determine accord local regulation participate country . Healthy subject establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Child care . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . For corticosteroid , ≥10 mg/day prednisone equivalent . Inhaled topical steroid allow . Planned administration/administration vaccine foreseen study protocol within period start 30 day end 30 day study dose vaccine ( ) , exception license inactivated influenza vaccine . Concurrently participate another clinical study , time study period , subject expose investigational product noninvestigational vaccine/product . Previous vaccination meningococcal polysaccharide conjugate vaccine within last 10 year . History meningococcal disease since birth . History serious allergic reaction follow DTPcontaining vaccine component study vaccine . History encephalopathy within seven day administration previous pertussis antigencontaining vaccine attributable another identifiable cause . Persons experience Arthustype hypersensitivity reaction follow prior dose tetanustoxoid contain vaccine receive Boostrix unless least 10 year elapse since last dose tetanustoxoid contain vaccine . Previous vaccination tetanustoxoid contain vaccine within previous five year . Temperature ≥ 40.5°C ( 105°F ) within 48 hour receipt previous dose DTP vaccine ( diphtheriatetanuswhole cell pertussis [ DTPw ] and/or diphtheriatetanusacellular pertussis [ DTaP ] ) , due another identifiable cause . Collapse shocklike state within 48 hour receipt previous dose DTP vaccine . Seizures without fever within three day previous dose DTP vaccine . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , base medical history history direct physical examination . A family history congenital hereditary immunodeficiency , immune competence potential vaccine recipient demonstrate . History allergic disease/reaction hypersensitivity likely exacerbate component vaccine ( ) . Progressive neurologic disorder , unstable neurologic condition , uncontrolled epilepsy progressive encephalopathy . History neurologic disorder seizure . A history ADHD depression history single , simple febrile seizure exclude subject . Major congenital defect serious chronic illness . Previous history GuillainBarré Syndrome . Bleeding disorder , hemophilia thrombocytopenia , subject anticoagulant therapy . Acute disease and/or fever time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Previous vaccination HPV , plan administration HPV vaccine foreseen study protocol study period . Previous administration MPL AS04 adjuvant . History chronic alcohol consumption and/or drug abuse . Pregnant lactate female . A subject planning become pregnant , likely become pregnant planning discontinue contraceptive precaution study period two month last vaccine dose . Subjects must least three month postpregnancy breastfeed enter study .</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pertussis</keyword>
	<keyword>Meningococcal meningitis</keyword>
	<keyword>Meningococcal infection</keyword>
	<keyword>HPV</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Vaccines , conjugate</keyword>
	<keyword>tetanus</keyword>
	<keyword>diphtheria</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>